Auxilium Pharmaceuticals Inc

Auxilium Pharmaceuticals — JP Morgan Healthcare Conference 2012

31 slides from Auxilium Pharmaceuticals's conference presentation, Jan 9, 2012

  1. Slide 1: JP Morgan 2012

    Slide 1: JP Morgan 2012

    JP Morgan 2012 (NASDAQ: AUXL) Exhibit 99.1

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement We will make various remarks relating to our current plans, potential future events, and what we believe to be the prospects for the Company in this presentation that constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities L

  3. Slide 3: Auxilium – A Company Overview

    Slide 3: Auxilium – A Company Overview

    Auxilium – A Company Overview Fully integrated specialty biopharmaceutical company, ~550 employees including a sales force of ~250 2010 global net revenues of $211.4 million; CAGR of 39.4% over past six years revenue guidance of $254 – million Testim® XIAFLEX® › Testosterone replacement therapy gel

  4. Slide 4: Auxilium – Vision and Growth Strategy

    Slide 4: Auxilium – Vision and Growth Strategy

    Auxilium – Vision and Growth Strategy Deliver on Current Pipeline Maximize Value of Testim and XIAFLEX Build Out Pipeline in Specialty Therapeutic Areas Shareholder Value Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Bio-Pharmaceutical Company

  5. Slide 5: Auxilium – Vision and Growth Strategy

    Slide 5: Auxilium – Vision and Growth Strategy

    Auxilium – Vision and Growth Strategy Deliver on Current Pipeline Maximize Value of Testim and XIAFLEX Build Out Pipeline in Specialty Therapeutic Areas Shareholder Value Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Bio-Pharmaceutical Company

  6. Slide 6: Taking Advantage of Global Opportunities Through Licensing Partnerships

    Slide 6: Taking Advantage of Global Opportunities Through Licensing Partnerships

    Taking Advantage of Global Opportunities Through Licensing Partnerships U.S. Canada EU Japan R.O.W. Exploring Opportunities

  7. Slide 7: Testim – Product and Market Overview

    Slide 7: Testim – Product and Market Overview

    Testim – Product and Market Overview 1% testosterone gel indicated for testosterone replacement therapy (TRT) in adult males for hypogonadism Launched in U.S. in 2003 and EU in 2005 TRT market value has grown at 25.4% CAGR since 2005 > 8 years of use with established safety and efficacy › ~115M dail

  8. Slide 8: TRT Landscape is Changing

    Slide 8: TRT Landscape is Changing

    TRT Landscape is Changing New competition helping increase overall market in 2011 - 17% y/y prescription growth in 3Q11 Aggressive strategy in select managed care plans has helped Testim minimize market share loss to new players Despite loss of market share to new entrants, Testim revenues through S

  9. Slide 9: Testim Strategy Focuses on the Top TRT Prescribers

    Slide 9: Testim Strategy Focuses on the Top TRT Prescribers

    Testim Strategy Focuses on the Top TRT Prescribers 13% ~156K ~3,200K ~700K 50% Testim Market Share 72% Source: IMS Prescriber Plan Trak 12 month rolling estimates through November TRT Prescribers Gel TRx Testim TRx ~ 21% total gel TRT market share ~ 31% market share in targets ~ 12% market share in

  10. Slide 10: XIAFLEX - A Paradigm-Changing, Minimally Invasive Treatment

    Slide 10: XIAFLEX - A Paradigm-Changing, Minimally Invasive Treatment

    XIAFLEX - A Paradigm-Changing, Minimally Invasive Treatment XIAFLEX - A Paradigm-Changing, Minimally Invasive Treatment Approved to treat adults with Dupuytren’s contracture when a cord can be felt A mixture of collagenases injected directly into Dupuytren's cord Commercial launch in U.S. in March 2

  11. Slide 11: Dupuytren's Contracture - A Debilitating Disease

    Slide 11: Dupuytren's Contracture - A Debilitating Disease

    Dupuytren’s Contracture - A Debilitating Disease Excessive collagen causing reduced elasticity in fascia of hand with nodules or pits as an early, active presentation Rope-like cords develop in the finger and result in contractures affecting quality of life and daily activities Fasciectomy is an inv

  12. Slide 12: XIAFLEX - Provides Surgeons With A Minimally Invasive Tool

    Slide 12: XIAFLEX - Provides Surgeons With A Minimally Invasive Tool

    XIAFLEX - Provides Surgeons With A Minimally Invasive Tool Pre-XIAFLEX injection 30 days following XIAFLEX injection Simple injection and manipulation procedure Established mechanism of actions and selective for specific types of collagen Efficient use of surgeon’s time No active physical therapy re

  13. Slide 13: Adoption of XIAFLEX is Growing

    Slide 13: Adoption of XIAFLEX is Growing

    Adoption of XIAFLEX is Growing ~58% of enrolled sites have ordered XIAFLEX PHYSICIAN ENROLLMENTS SITES ENROLLED UNIQUE SITES ORDERING

  14. Slide 14: Steady Growth in Experienced Sites

    Slide 14: Steady Growth in Experienced Sites

    Steady Growth in Experienced Sites Cumulative Injections per Site

  15. Slide 15: Strategies for Establishing XIAFLEX as the Standard of Care

    Slide 15: Strategies for Establishing XIAFLEX as the Standard of Care

    Strategies for Establishing XIAFLEX as the Standard of Care • Compelling clinical efficacy and safety data • Facilitate peer-to-peer dialogue • Activate a critical mass of experienced prescribers • Sample program for XIAFLEX-naïve physicians • Multi-cord phase IV clinical study initiated • Patient c

  16. Slide 16: Auxilium – Vision and Growth Strategy

    Slide 16: Auxilium – Vision and Growth Strategy

    Auxilium – Vision and Growth Strategy Deliver on Current Pipeline Maximize Value of Testim and XIAFLEX Build Out Pipeline in Specialty Therapeutic Areas Shareholder Value Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Bio-Pharmaceutical Company

  17. Slide 17: XIAFLEX - Pipeline Opportunities

    Slide 17: XIAFLEX - Pipeline Opportunities

    XIAFLEX - Pipeline Opportunities Top-line phase III data in 2Q12 Top-line phase IIa data in 1H13 Clinical trials to start soon Clinical trials to start soon Begin phase Ib in 1Q12, data in 2H12 LATE RESEARCH PRE-CLINICAL PHASE I PHASE II PHASE III * Right to exercise option for exclusive global lice

  18. Slide 18: Peyronie's Disease: A Devastating Disorder

    Slide 18: Peyronie's Disease: A Devastating Disorder

    Peyronie’s Disease: A Devastating Disorder Scarring phenomenon affecting the tunica albuginea Plaques show excessive collagen deposition Potential symptoms: › Pain with erection, penile curvature/deviation, penile shortening, indentations, and/or erectile dysfunction › May have difficulty with sexua

  19. Slide 19: Peyronie's Phase IIb Efficacy Results (2009)

    Slide 19: Peyronie's Phase IIb Efficacy Results (2009)

    Peyronie’s Phase IIb Efficacy Results (2009) Penile curvature and domains of the patient reported outcomes (PRO) survey were measured › Three dosing cycles – up to six injections › Penile modeling was compared to no modeling In all subjects, penile curvature and Peyronie’s disease bother, a PRO doma

  20. Slide 20: Changes to the Phase IIb Trial Design Should Increase the Chance of Success in Phase III

    Slide 20: Changes to the Phase IIb Trial Design Should Increase the Chance of Success in Phase III

    Changes to the Phase IIb Trial Design Should Increase the Chance of Success in Phase III Mean net improvements in phase IIb penile curvature and bother domain for modeling arm would have met statistical significance using phase III co-primary endpoint requirements 4 cycles of therapy in the Phase II

  21. Slide 21: Peyronie's Disease: Pivotal Phase III Update

    Slide 21: Peyronie's Disease: Pivotal Phase III Update

    Peyronie’s Disease: Pivotal Phase III Update Active dosing phase complete Double-blind patients complete 52 week follow-up phase in March 2012 Top-line results should be available in 2Q12 sBLA filing expected by end of 2012 Potential commercial launch planned in late 2013

  22. Slide 22: Edematous Fibrosclerotic Panniculopathy (EFP) Represents a Compelling Opportunity

    Slide 22: Edematous Fibrosclerotic Panniculopathy (EFP) Represents a Compelling Opportunity

    Edematous Fibrosclerotic Panniculopathy (EFP) Represents a Compelling Opportunity There are currently no FDA-approved medical therapies for EFP, commonly known as cellulite Current non-surgical options haven’t shown benefit › OTC pills, creams and lotions › Unapproved mixtures of enzymes and fat dis

  23. Slide 23: Frozen Shoulder Syndrome: An Unmet Medical Need

    Slide 23: Frozen Shoulder Syndrome: An Unmet Medical Need

    Frozen Shoulder Syndrome: An Unmet Medical Need Current treatment options have limited results › Non-steroidal pain relievers › Oral steroids › Corticosteroid injections › Physical therapy Manipulation of the shoulder under anesthesia, long-term intensive physical therapy or arthroscopic surgery can

  24. Slide 24: Auxilium- Vision and Growth Strategy

    Slide 24: Auxilium- Vision and Growth Strategy

    Auxilium- Vision and Growth Strategy Deliver on Current Pipeline Maximize Value of Testim and XIAFLEX Build Out Pipeline in Specialty Therapeutic Areas Shareholder Value Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Bio-Pharmaceutical Company

  25. Slide 25: Business Development Efforts Focused on Building Out Pipeline

    Slide 25: Business Development Efforts Focused on Building Out Pipeline

    Business Development Efforts Focused on Building Out Pipeline Leverage current infrastructure of Testim and XIAFLEX field forces with in-licensed marketed products Seeking phase II and later assets for specialty markets (Urology, Orthopedics) and Orphan diseases

  26. Slide 26: Financials

    Slide 26: Financials

    Financials Financials

  27. Slide 27: 3Q11 Net Revenues Up 24% over 3Q10

    Slide 27: 3Q11 Net Revenues Up 24% over 3Q10

    3Q11 Net Revenues Up 24% over 3Q10 $53.6 $66.7 +24%

  28. Slide 28: Auxilium - Q3 2011 Financial Results

    Slide 28: Auxilium - Q3 2011 Financial Results

    Auxilium - Q3 2011 Financial Results ** Weighted average common shares were 47,592,975 in Q3 and 47,933,447 in Q3 2011. Total revenues $53.6 $66.7 +24% Cost of goods sold* 11.6 13.5 +17% Gross Profit $42.1 $53.2 +26% % of revenues 78% 80% Operating expenses: Research and development* 14.4 14.2 -2% S

  29. Slide 29: Auxilium - 2011 Preliminary Net Revenue

    Slide 29: Auxilium - 2011 Preliminary Net Revenue

    Auxilium - 2011 Preliminary Net Revenue Global net revenues should be above midpoint of previously issued guidance of $254 to 271 million and slightly above current 2011 sell side consensus of $263.9 million. Global Testim net revenues should be above midpoint of previously issued guidance of $200 t

  30. Slide 30: Auxilium - Strategic Priorities to Drive Long - Term Growth

    Slide 30: Auxilium - Strategic Priorities to Drive Long - Term Growth

    Auxilium - Strategic Priorities to Drive Long - Term Growth Maximize Testim revenue growth in a changing competitive environment Establish XIAFLEX as the standard of care for Dupuytren’s contracture in the U.S. Support Pfizer’s launch of XIAPEX for the treatment of Dupuytren’s contracture Complete P

  31. Slide 31: Auxilium - Investment Rationale

    Slide 31: Auxilium - Investment Rationale

    Auxilium - Investment Rationale Track record of developing and commercializing novel treatments for unmet medical needs Pipeline with five potential new XIAFLEX indications in development Global commercialization through licensing partnerships Opportunity to build urology, orthopedics and other spec

Source: SEC EDGAR · 8-K filed Jan 9, 2012

More decks from Auxilium Pharmaceuticals Inc